Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ibrutinib Results Suggest Potential To Shake Up CLL Market

Executive Summary

Momentum builds for Pharmacyclics/J&J’s ibrutinib with release of new data at the American Society of Hematology meeting, suggesting the drug has a shot at accelerated approval in sub-populations with high unmet need and potential in a range of B-cell cancers. Profiles of competitors from Gilead and Infinity/Takeda also came into greater focus at ASH.

You may also be interested in...



Novel CLL Drugs Jockey For Position In Tomorrow’s Revolutionized Market

Gilead’s idelalisib, Roche’s Gazyva and Infinity’s IPI-145 are among a wave of new drugs promising to transform the way the disease is treated across lines of therapy.

Ibrutinib’s Clean Label For Mantle Cell Leukemia Bodes Well For CLL Claim

Pharmacyclics/Janssen’s Imbruvica carries a high list price, but also patient support.

Sizing Up The Competition In BTK Inhibition

Celgene’s latest Phase I dose-ranging data for the BTK inhibitor CC-292 show better response rates than before. The BTK target has become highly attractive, yet the competitive landscape for this particular class still looks sparse, with four drugs in the clinic and two slated for INDs in 2014.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel